CN119156389A - 杂环化合物、其组合物和其治疗方法 - Google Patents

杂环化合物、其组合物和其治疗方法 Download PDF

Info

Publication number
CN119156389A
CN119156389A CN202380038288.9A CN202380038288A CN119156389A CN 119156389 A CN119156389 A CN 119156389A CN 202380038288 A CN202380038288 A CN 202380038288A CN 119156389 A CN119156389 A CN 119156389A
Authority
CN
China
Prior art keywords
compound
mmol
substituted
unsubstituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380038288.9A
Other languages
English (en)
Chinese (zh)
Inventor
喻超
孙汉资
王策
王志伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beone Pharmaceutical Suzhou Co Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of CN119156389A publication Critical patent/CN119156389A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380038288.9A 2022-05-05 2023-05-04 杂环化合物、其组合物和其治疗方法 Pending CN119156389A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022090877 2022-05-05
CNPCT/CN2022/090877 2022-05-05
PCT/CN2023/092047 WO2023213271A1 (en) 2022-05-05 2023-05-04 Heterocyclic compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
CN119156389A true CN119156389A (zh) 2024-12-17

Family

ID=88646299

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380038288.9A Pending CN119156389A (zh) 2022-05-05 2023-05-04 杂环化合物、其组合物和其治疗方法

Country Status (5)

Country Link
US (1) US20250066372A1 (enExample)
EP (1) EP4519267A4 (enExample)
JP (1) JP2025517629A (enExample)
CN (1) CN119156389A (enExample)
WO (1) WO2023213271A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025024388A1 (en) 2023-07-21 2025-01-30 Accutar Biotechnology Inc. Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors
WO2025024726A1 (en) * 2023-07-26 2025-01-30 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinase
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319102B1 (en) * 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
CA2954189A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
WO2020140052A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
EP3956031A1 (en) * 2019-04-19 2022-02-23 Pfizer Inc. Anti-proliferative agents for treating pah
CN112125911B (zh) * 2020-09-24 2022-08-09 深圳湾实验室坪山生物医药研发转化中心 Cdk9抑制剂及其制备方法与应用

Also Published As

Publication number Publication date
WO2023213271A1 (en) 2023-11-09
US20250066372A1 (en) 2025-02-27
JP2025517629A (ja) 2025-06-10
EP4519267A4 (en) 2026-02-25
EP4519267A1 (en) 2025-03-12

Similar Documents

Publication Publication Date Title
JP7833597B2 (ja) Ｃｄｋ２阻害剤としての二環式アミン
US20250221996A1 (en) Heterocyclic compounds, compositions thereof, and methods of treatment therewith
US10253046B2 (en) TYK2 inhibitors and uses thereof
CA2845159C (en) Compounds and compositions as c-kit kinase inhibitors
CN112955459A (zh) 双环肽配体和其用途
US20250066372A1 (en) Heterocyclic compounds, compositions thereof, and methods of treatment therewith
TWI822713B (zh) 適用於治療或預防與其相關之病症之β－３腎上腺素受體的調節劑
EP3694330B1 (en) Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
US8895571B2 (en) Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors
CN113271938A (zh) Tyk2抑制剂和其用途
US20250000860A1 (en) Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
JP2025111694A (ja) Ｔｙｋ２阻害剤およびその使用
KR20100019489A (ko) Ｐｉ３ｋ 지질 키나제 억제제로서의 치환된 이미다조피리다진
MX2008014531A (es) Pirazolopirimidinas sustituidas.
CA2729745A1 (en) Oxindole compounds
EP3971190A1 (en) Heterocycle-fused pyrimidine derivative and use thereof
CN118201929A (zh) Protac化合物、含其的药物组合物及其制备方法和应用
CN112424203A (zh) 布鲁顿酪氨酸激酶抑制剂
WO2016090079A1 (en) Heteroaryl compounds and uses thereof
BR112019015314A2 (pt) compostos para inibir a atividade da quinase lrrk2
TW202104224A (zh) 用於治療pah之抗增生藥劑
US20230122807A1 (en) Btk inhibitors
CN119462641A (zh) 用于制备杂环化合物的方法
WO2025240238A1 (en) Thieno[3,4-d]pyrimidin-4-amine inhibitors of hck
EP4194450A1 (en) Cdk9 inhibitor and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20251022

Address after: 215002 Jiangsu Province Suzhou City China (Shanghai) Pilot Free Trade Zone Suzhou Area Suzhou Industrial Park Jinhai Road 29.NO

Applicant after: Baiji Shenzhou (Suzhou) Biotechnology Co.,Ltd.

Country or region after: China

Address before: 94 sonaris Avenue, kamana Bay, grand caiman, British Isles

Applicant before: BEIGENE, Ltd.

Country or region before: Cayman Islands